Evidence map›Paper›PMID 30122019›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2018

[Effect of PD-1 inhibitor Nivolumab on the proliferation and cytotoxicity of anti-CD19 chimeric antigen receptor T cells].

H B Zhu, Q Deng, R Zhang, Y Y Jiang, J X Meng, M F Zhao, Y M Li, R Cui

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

H B ZhuDepartment of Hematology, Tianjin First Central Hospital, Tianjin 300192, China.
Q Deng
R Zhang
Y Y Jiang
J X Meng
M F Zhao
Y M Li
R Cui
Tianjin Medical University · CN

Funding

and Frontier Technology Research Project 15JCQNJC45500Key Projects of Tianjin Municipal Health Planing Commission 16KG110Science and Technology Fund of Tianjin Municipal Health Bureau 15KG135
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antigens, CD19Cell ProliferationHumansLeukocytes, MononuclearNivolumabProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellReceptors, Chimeric AntigenT-LymphocytesAntigens, CD19NivolumabProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellReceptors, Chimeric AntigenChimeric antigen receptorLymphomaPD-1 inhibitor

Identifiers

PMID30122019
PMCPMC7342209
OpenAlexW3010262241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.